+34 620 10 75 37info@nanbiosis.com

Nanbiosis Committees


Coordination Committee

  • Jaume Veciana, Scientific Director of NANBIOSIS; Director of  Molecular Nanosciences and Organic Materials Dpt. (ICMAB-CSIC)  and Coordinator of Platform Programme of CIBER BBN.
  • Francisco Miguel Sánchez Margallo; Assistant Director of NANBIOSIS and Scientific Director of JUMISC
  • Ramón Martínez Máñez, Scientific Director of CIBER-BBNPI of  the Group of Applied Molecular Chemistry Center of Molecular Recognition and Technological Development of the Polytechnic University of Valencia (UPV-ADM-IQMA) Scientific Director of NANBIOSIS Unit 26
  • María Luisa García Martín, Scientific Director of NANBIOSIS Unit 28, PI of the Group Biomedical Magnetic Resonance Laboratory-BIONAND,
  • Pablo Laguna, Scientific Director of NANBIOSIS Unit 27, PI of the Biomedical Signal Interpretation and Computational Simulation (BSICoS) group; Scientific Coordinator of  I3A (Aragon Institute of Engineering Research)
  • Verónica Crisóstomo, Researcher at the Endoluminal Diagnostic and Therapeutic Unit of the Minimally Invasive Surgery Center Jesús Usón.


Scientific-Technical Advisory Board

  • Begoña Castro, Scientific Director of Histocell, Madrid
  • Pilar Calvo, Pharmaceutical Development Manager of PHARMAMAR
  • Anton Ussi, Operations and Finance Director at EATRIS ERIC, the European Infrastructure for Translational Medicine, Amsterdam, The Netherlands
  • Ruth Schmid. Vicepresident SINTEF, Norway
  • Jürguen Borlak, Director of Institute for Pharmaco- and Toxicogenomics, Hannover Medical School, Germany
  • Stefania Raimondo, Professor at the University of Turin, Italy
  • Anna Bigas, Scientific Director o CIBERONC and researcher at IMIM
  • Ignacio Santiago Álvarez, Professor of the University of Extremadura / Scientific Director IERA-GC, Badajoz
  • Francisco Fernández Avilés, Chair of the Department of Cardiology, University Hospital Gregorio Marañón, Madrid
  • Antonio Bernad, Research Professor at Immunology and Oncology Department, National Center for Biotechnology (CNB), Madrid
  • Pedro Pesini, Senior Manager, Scientific Affairs en Araclon Biotech-Grifols


Access Committee

  • Joan Bausells, Research Professor at the Institute of Microelectronics of Barcelona, CSIC.
  • Mª Eugenia Fernández Santos, Director of Advanced Therapy Medicinal Products Production Unit and Regenerative Medicine-GMP facilities of Gregorio Marañón Hospital, Madrid
  • Angel Maquieira, Research Professor at the Polytechnic University of Valencia
  • Javier García Casado, Associate Professor at the University of Extremadura, Cáceres, Spain
  • Jose Maria Perez Pomares, Professor and Director of the Department of Animal Biology at the University of Malaga